Advertisement
| canadian agency for drugs and technologies in health: Patient Involvement in Health Technology Assessment Karen M. Facey, Helle Ploug Hansen, Ann N.V. Single, 2017-05-15 This is the first book to offer a comprehensive guide to involving patients in health technology assessment (HTA). Defining patient involvement as patient participation in the HTA process and research into patient aspects, this book includes detailed explanations of approaches to participation and research, as well as case studies. Patient Involvement in HTA enables researchers, postgraduate students, HTA professionals and experts in the HTA community to study these complementary ways of taking account of patients’ knowledge, experiences, needs and preferences. Part I includes chapters discussing the ethical rationale, terminology, patient-based evidence, participation and patient input. Part II sets out methodology including: Qualitative Evidence Synthesis, Discrete Choice Experiments, Analytical Hierarchy Processes, Ethnographic Fieldwork, Deliberative Methods, Social Media Analysis, Patient-Reported Outcome Measures, patients as collaborative research partners and evaluation. Part III contains 15 case studies setting out current activities by HTA bodies on five continents, health technology developers and patient organisations. Each part includes discussion chapters from leading experts in patient involvement. A final chapter reflects on the need to clearly define the goals for patient involvement within the context of the HTA to identify the optimal approach. With cohesive contributions from more than 80 authors from a variety of disciplines around the globe, it is hoped this book will serve as a catalyst for collaboration to further develop patient involvement to improve HTA. If you’re not involving patients, you're not doing HTA! - Dr. Brian O’Rourke, President and CEO of CADTH, Chair of INAHTA |
| canadian agency for drugs and technologies in health: Decision Making in a World of Comparative Effectiveness Research Howard G. Birnbaum, Paul E. Greenberg, 2018-07-29 In the past decade there has been a worldwide evolution in evidence-based medicine that focuses on real-world Comparative Effectiveness Research (CER) to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on research findings, data and methods, Howard Birnbaum and Paul Greenberg (both of Analysis Group) have edited a book that provides a practical guide to decision making using the results of analysis and interpretation of CER. Decision Making in a World of Comparative Effectiveness contains chapters by senior industry executives, key opinion leaders, accomplished researchers, and leading attorneys involved in resolving disputes in the life sciences industry. The book is aimed at 'users' and 'decision makers' involved in the life sciences industry rather than those doing the actual research. This book appeals to those who commission CER within the life sciences industry (pharmaceutical, biologic, and device manufacturers), government (both public and private payers), as well as decision makers of all levels, both in the US and globally. |
| canadian agency for drugs and technologies in health: Medical Technology in Canada Nadeem Esmail, 2008 This study reviews various national and international studies to evaluate the availability of medical technologies in Canada relative to other countries, analyzes data produced by the Canadian Institute for Health Information (CIHI) to measure both the age and sophistication of medical technologies in Canada, and discusses a survey undertaken for this research paper that measures the stock of cutting-edge medical technologies in Canada's five largest cities. |
| canadian agency for drugs and technologies in health: WHO Recommendation on Umbilical Vein Injection of Oxytocin for the Treatment of Retained Placenta , 2020 Efforts to prevent and reduce morbidity and mortality due to PPH (Postpartum haemorrhage) can help to address the profound inequities in maternal and perinatal health globally. To achieve this, skilled health personnel, health managers, policy-makers and other stakeholders need up-to-date and evidence-informed recommendations to guide clinical policies and practices. In 2019, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating of the existing WHO recommendation: Umbilical vein injection of oxytocin for the treatment of retained placenta, in response to the availability of new evidence. The recommendation in this document thus supersedes the previous WHO recommendations on intraumbilical vein injection of oxytocin for treatment of retained placenta as published in the 2012 guideline, WHO recommendations for the prevention and treatment of postpartum haemorrhage. |
| canadian agency for drugs and technologies in health: Health Systems in Transition Third Edition Gregory P. Marchildon, Sara Allin, Sherry Merkur, 2021-04-21 This book provides insight into how the Canadian health care system is financed and organized, how it has evolved over time, and how well it performs relative to peer countries. |
| canadian agency for drugs and technologies in health: Orphan Drugs and Rare Diseases David Pryde, Michael J Palmer, 2014-07-30 Orphan drugs are designated drug substances that are intended to treat rare or ‘orphan’ diseases. More than 7000 rare diseases are known that collectively affect some 6-7% of the developed world’s population; however, individually, any single, rare disease may only affect a handful of people making them commercially unattractive for the biopharmaceutical industry to target. Ground breaking legislation, starting with the Orphan Drug Act that was passed in the US in 1983 to provide financial incentives for companies to develop orphan drugs, has sparked ever increasing interest from biopharmaceutical companies to tackle rare diseases. These developments have made rare diseases, and the orphan drugs that treat them, sufficiently attractive to pharmaceutical development and many pharmaceutical companies now have research units dedicated to this area of research. It is therefore timely to review the area of orphan drugs and some of the basic science, drug discovery and regulatory factors that underpin this important, and growing, area of biomedical research. Written by a combination of academic and industry experts working in the field, this text brings together expert authors in the regulatory, drug development, genetics, biochemistry, patient advocacy group, medicinal chemistry and commercial domains to create a unique and timely reference for all biomedical researchers interested in finding out more about orphan drugs and the rare diseases they treat. Providing an up-to-date monograph, this book covers the basic science, drug discovery and regulatory elements behind orphan drugs and will appeal to medicinal and pharmaceutical chemists, biochemists and anyone working within the fields of rare disease research and drug development or pharmaceuticals in industry or academia. |
| canadian agency for drugs and technologies in health: Ontario's Health System John Lavis, 2016-12 |
| canadian agency for drugs and technologies in health: FDA in the Twenty-First Century Holly Fernandez Lynch, I. Glenn Cohen, 2015-09-08 In its decades-long effort to assure the safety, efficacy, and security of medicines and other products, the Food and Drug Administration has struggled with issues of funding, proper associations with industry, and the balance between consumer choice and consumer protection. Today, these challenges are compounded by the pressures of globalization, the introduction of novel technologies, and fast-evolving threats to public health. With essays by leading scholars and government and private-industry experts, FDA in the Twenty-First Century addresses perennial and new problems and the improvements the agency can make to better serve the public good. The collection features essays on effective regulation in an era of globalization, consumer empowerment, and comparative effectiveness, as well as questions of data transparency, conflicts of interest, industry responsibility, and innovation policy, all with an emphasis on pharmaceuticals. The book also intervenes in the debate over off-label drug marketing and the proper role of the FDA before and after a drug goes on the market. Dealing honestly and thoroughly with the FDA's successes and failures, these essays rethink the structure, function, and future of the agency and the effect policy innovations may have on regulatory institutions abroad. |
| canadian agency for drugs and technologies in health: Health Technology Assessment Robert B. Hopkins MA MBA PhD, Ron Goeree MA, 2015-04-10 The term health technology refers to drugs, devices, and programs that can improve and extend quality of life. As decision-makers struggle to find ways to reduce costs while improving health care delivery, health technology assessments (HTA) provide the evidence required to make better-informed decisions.This is the first book that focuses on the s |
| canadian agency for drugs and technologies in health: Clinical Practice Guidelines We Can Trust Institute of Medicine, Board on Health Care Services, Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, 2011-06-16 Advances in medical, biomedical and health services research have reduced the level of uncertainty in clinical practice. Clinical practice guidelines (CPGs) complement this progress by establishing standards of care backed by strong scientific evidence. CPGs are statements that include recommendations intended to optimize patient care. These statements are informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options. Clinical Practice Guidelines We Can Trust examines the current state of clinical practice guidelines and how they can be improved to enhance healthcare quality and patient outcomes. Clinical practice guidelines now are ubiquitous in our healthcare system. The Guidelines International Network (GIN) database currently lists more than 3,700 guidelines from 39 countries. Developing guidelines presents a number of challenges including lack of transparent methodological practices, difficulty reconciling conflicting guidelines, and conflicts of interest. Clinical Practice Guidelines We Can Trust explores questions surrounding the quality of CPG development processes and the establishment of standards. It proposes eight standards for developing trustworthy clinical practice guidelines emphasizing transparency; management of conflict of interest ; systematic review-guideline development intersection; establishing evidence foundations for and rating strength of guideline recommendations; articulation of recommendations; external review; and updating. Clinical Practice Guidelines We Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care. This book contains information directly related to the work of the Agency for Healthcare Research and Quality (AHRQ), as well as various Congressional staff and policymakers. It is a vital resource for medical specialty societies, disease advocacy groups, health professionals, private and international organizations that develop or use clinical practice guidelines, consumers, clinicians, and payers. |
| canadian agency for drugs and technologies in health: Finding What Works in Health Care Institute of Medicine, Board on Health Care Services, Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, 2011-07-20 Healthcare decision makers in search of reliable information that compares health interventions increasingly turn to systematic reviews for the best summary of the evidence. Systematic reviews identify, select, assess, and synthesize the findings of similar but separate studies, and can help clarify what is known and not known about the potential benefits and harms of drugs, devices, and other healthcare services. Systematic reviews can be helpful for clinicians who want to integrate research findings into their daily practices, for patients to make well-informed choices about their own care, for professional medical societies and other organizations that develop clinical practice guidelines. Too often systematic reviews are of uncertain or poor quality. There are no universally accepted standards for developing systematic reviews leading to variability in how conflicts of interest and biases are handled, how evidence is appraised, and the overall scientific rigor of the process. In Finding What Works in Health Care the Institute of Medicine (IOM) recommends 21 standards for developing high-quality systematic reviews of comparative effectiveness research. The standards address the entire systematic review process from the initial steps of formulating the topic and building the review team to producing a detailed final report that synthesizes what the evidence shows and where knowledge gaps remain. Finding What Works in Health Care also proposes a framework for improving the quality of the science underpinning systematic reviews. This book will serve as a vital resource for both sponsors and producers of systematic reviews of comparative effectiveness research. |
| canadian agency for drugs and technologies in health: Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy World Health Organization, 2015-04-20 These guidelines have been developed to enable professionals to assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder, to achieve healthy outcomes for themselves and their fetus or infant. They have been developed in response to requests from organizations, institutions and individuals for technical guidance on the identification and management of alcohol, and other substance use and substance use disorders in pregnant women. They were developed in tandem with the WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy. |
| canadian agency for drugs and technologies in health: Pharmacoepidemiology Brian L. Strom, Stephen E. Kimmel, Sean Hennessy, 2019-12-16 Dieses Lehrbuch, ein wegweisender Klassiker, bietet in der 6. Auflage noch mehr Inhalte für Leser, die aktuelle Informationen zur Pharmakoepidemiologie benötigen. Die vorliegende Auflage wurde vollständig überarbeitet und aktualisiert. Sie bietet einen Überblick über sämtliche Facetten des Fachgebiets, aus Sicht von Lehre und Forschung, aus Sicht der Industrie und von Regulierungsbehörden. Datenquellen, Anwendungen und Methodiken werden verständlich erläutert. |
| canadian agency for drugs and technologies in health: Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade World Intellectual Property Organization, 2013 This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies. |
| canadian agency for drugs and technologies in health: The Right Price Peter J. Neumann, Joshua T. Cohen, Daniel A. Ollendorf, 2021 The prescription drug market -- Proposed solutions for rising drug prices -- Measuring the value of prescription drugs -- Measuring drug value : whose job is it anyway? -- Institute for Clinical and Economic Review (ICER) -- Other US value assessment frameworks -- Do drugs for special populations warrant higher prices? -- Improving value measurement -- Aligning prices with value -- The path forward. |
| canadian agency for drugs and technologies in health: Hospital-Based Health Technology Assessment Laura Sampietro-Colom, Janet Martin, 2017-01-23 A timely work describing how localized hospital-based health technology assessment (HB-HTA) complements general, ‘arms-length’ HTA agency efforts, and what has been the collective global impact of HB-HTA across the globe. While HB-HTA has gained significant momentum over the past few years, expertise in the field, and information on the operation and organization of HB-HTA, has been scattered. This book serves to bring this information together to inform those who are currently working in the field of HTA at the hospital, regional, national or global level. In addition, this book is intended for decision-makers and policy-makers with a stake in determining the uptake and decommissioning of new and established technologies in the hospital setting. HTA has traditionally been performed at the National/Regional level by HTA Agencies, typically linked to governments. Yet hospitals are the main entry door for most health technologies (HTs). Hospital decision-makers must undertake multiple high stakes investment and disinvestment decisions annually for innovative HTs, usually without adequate information. Despite the existence of arms-length HTA Agencies, inadequate information is available to hospital decision-makers either because relevant HTA reports are not yet released at the time of entry of new technologies to the field, or because even when the report exists, the information contained is insufficient to clarify the contextualized informational needs of hospital decision makers. Therefore, there has recently been a rising trend toward hospital-based HTA units and programs. These units/programs complement the work of National/Regional HTA Agencies by providing the key and relevant evidence needed by hospital decision makers in their specific hospital context, and within required decision-making timelines. The emergence of HB-HTA is creating a comprehensive HTA ecosystem across health care levels, which creates better bridges for knowledge translation through relevance and timeliness. |
| canadian agency for drugs and technologies in health: Health Care in Canada Katherine Fierlbeck, 2011-01-01 Health Care in Canada examines the challenges faced by the Canadian health care system, a subject of much public debate. In this book Katherine Fierlbeck provides an in-depth discussion of how health care decisions are shaped by politics and why there is so much disagreement over how to fix the system. Many Canadians point to health care as a source of national pride; others are highly critical of the system's shortcomings and call for major reform. Yet meaningful debate cannot occur without an understanding of how the system actually operates. In this overview, Fierlbeck outlines the basic framework of the health care system with reference to specific areas such as administration and governance, public health, human resources, drugs and drug policy, and mental health. She also discusses alternative models in other countries such as Britain, the United States, and France. As health care becomes increasingly complex, it is crucial that Canadians have a solid grasp of the main issues within both the policy and political environments. With its balanced and accessible assessment of the main political and theoretical debates, Health Care in Canada is an essential guide for anyone with a stake in Canada's health system. |
| canadian agency for drugs and technologies in health: Health and Health Care Delivery in Canada Valerie D. Thompson, RN, PHC, NP, 2015-04-20 No health care professional in Canada should be without a clear understanding of the Canadian health care system! Health and Health Care Delivery in Canada, 2nd Edition explores the nation's basic approach to health, wellness, and illness. Set entirely within a Canadian context, this text includes coverage of individual and population health, the role of federal agencies and provincial governments, health care funding, and current issues and future trends in health care. Written by experienced educator and nurse practitioner, Valerie Thompson, this textbook is ideal for all students beginning a career in health care. Clear, easy-to-understand approach to health care in Canada begins with an overview of health, wellness, and illness and proceeds through the fundamentals of the Canadian health care system, such as population health, ethical and legal issues, health care funding and principles, practice settings, and changing trends. Learning Outcomes outline the knowledge that you should gain in each chapter. Key Terms open each chapter and include page references for definitions. Student-friendly learning aids include summary tables and boxes, photographs, figures, and illustrations. Review questions at the end of every chapter test your comprehension of the material. Case examples provide real-world scenarios related to the chapter content. In The News boxes highlight landmark case law, research developments, emerging health issues, and ethical challenges. Thinking It Through questions ask you to critically consider key aspects of health and health care delivery. NEW! Coverage of issues and trends includes expanded information on mental health issues, aboriginal health, privatization, use of electronic health records, and interprofessional health care practice. |
| canadian agency for drugs and technologies in health: From Research to Reality The Expert Panel on the Approval and Use of Somatic Gene Therapies in Canada, 2020-11-05 From Research to Reality describes the stages involved in the approval and use of gene therapies in Canada, and examines challenges associated with regulatory oversight, manufacturing, access, and affordability, and identifies promising approaches to address them. |
| canadian agency for drugs and technologies in health: Public Health and Preventive Health Care in Canada Bonnie Fournier, Dr. Fareen Karachiwalla, 2020-02-26 Work more effectively with a complete understanding of Canadian public health! Shah's Public Health and Preventive Health Care in Canada, Sixth Edition examines health care policy in Canada and the issues and trends faced by today's health care professionals. It puts health promotion and prevention models into a historical perspective, with discussions including the evolution of national health insurance, determinants of health and disease, and approaches to achieving health for all. Written by educators Bonnie Fournier and Fareen Karachiwalla, and based on the work of noted author Dr. Chandrakant Shah, this text provides an excellent foundation in Canadian public health for nurses and other health care professionals. - Quintessentially Canadian content is designed especially for Canadian nursing and health care professionals. - Comprehensive coverage includes in-depth, current information on public health and preventive care topics. - End-of-chapter summaries reinforce your understanding of key health care concepts. - End-of-chapter references provide recommendations for further reading and research. - NEW! Full-colour design enhances illustrations and improves readability to better illustrate complex concepts. - NEW! Indigenous Health chapter. - NEW! Groups Experiencing Health Inequities chapter. - NEW! Pan-Canadian focus uses a community health perspective, discussing the social determinants of health, health equity, and health promotion in each chapter. - NEW! Learning tools include chapter outlines and learning objectives, key terms, practical exercises, critical thinking questions, and summary boxes such as Case Study, Research Perspective, In the News, Interprofessional Practice, Clinical Example, Real World Example, and Evidence-Informed Practice, plus key websites. - NEW! Evolve companion website. - NEW! Emerging infectious diseases (EID) and COVID-19 discussion and exercises on Evolve, offer insight into current and developing challenges facing public health. |
| canadian agency for drugs and technologies in health: Canadian Medicare Stephen Duckett, Adrian Peetoom, 2013-04-01 Medicare has been a crucial part of Canadian identity for nearly fifty years, and it stands in marked contrast to the US health system. But these facts alone do not protect it from dismissive swipes and criticisms, claims that the system is unsustainable, and even proposals to change medicare's fundamentals. In Canadian Medicare, Stephen Duckett and Adrian Peetoom show that the shared values underpinning medicare still provide a sound basis for the system's design. While medicare remains an important pillar of Canadian policy, changes can and must be made. The authors argue for improved primary care to better address increases in chronic diseases, a comprehensive strategy to provide care for the elderly, and the introduction of pharmacare. They demonstrate how, with proper investment, the health of Canadians can be maintained and even enhanced while the nation remains financially responsible. Accessibly written and clearly presented, Canadian Medicare is a call for Canadian citizens to improve on the foundation built by Tommy Douglas and Lester B. Pearson, to become more knowledgeable about their health care, and to let their politicians know that they need to act. |
| canadian agency for drugs and technologies in health: Health Systems in Transition: Canada, Third Edition Gregory Marchildon, Sara Allin, Sherry Merkur, 2021-04-07 The health care system in Canada receives a great deal of international attention, but it is subject to considerable critique and debate locally. Health Systems in Transition: Canada provides an insightful and objective analysis of the organization, governance, financing, and delivery of health care as well as comparisons between the Canadian system and others internationally. This book draws on a wide range of empirical studies and statistical data within Canada and across comparable countries to provide a thorough description of the many facets of health care in Canada. Drawing on the most reliable and recent data available, this study reveals the strengths and weakness of Canadian health care. This assessment is based on numerous comparisons of Canada to peer countries (Australia, France, Germany, Netherlands, Sweden, the United Kingdom, and the United States) and among provinces and territories within Canada. It will be of interest to scholars and students in Canada wanting to learn more about the largest and most celebrated public program, and for those outside Canada interested in comparative systems and policy research. |
| canadian agency for drugs and technologies in health: Treating Health Care Raisa Deber, 2018-01-18 Canada has been among the world leaders in recognizing the multiple factors that impact health. Focusing on Canada’s health care system, Raisa B. Deber provides brief descriptions of some key facts and concepts necessary to understand health care policy in Canada and place it in an international context. An accessible guide, Treating Health Care unpacks key concepts to provide informed discussions that help us understand and diagnose Canada’s health care system and to clarify which proposed changes are likely to improve it - and which are not. This book provides background information to clarify such concepts as: determinants of health; how health systems are organized and financed (including international comparisons); health economics; health ethics; and roles and responsibilities of different stakeholders, including government, providers, and patients. It then addresses some key issues, including equity, efficiency, access and wait times, quality improvement and patient safety, and coverage and payment models. Using analysis rather than advocacy, Deber provides a toolkit to help understand health care and health policy. |
| canadian agency for drugs and technologies in health: Medical Technology Assessment Directory Institute of Medicine, Council on Health Care Technology, 1988-02-01 For the first time, a single reference identifies medical technology assessment programs. A valuable guide to the field, this directory contains more than 60 profiles of programs that conduct and report on medical technology assessments. Each profile includes a listing of report citations for that program, and all the reports are indexed under major subject headings. Also included is a cross-listing of technology assessment report citations arranged by type of technology headings, brief descriptions of approximately 70 information sources of potential interest to technology assessors, and addresses and descriptions of 70 organizations with memberships, activities, publications, and other functions relevant to the medical technology assessment community. |
| canadian agency for drugs and technologies in health: Drugs & Media Robert C. MacDougall, 2011-11-24 We have developed into a culture that is over-reliant upon pharmaceutical and recreational drugs; where drugs are incessantly advertised and promoted to us via our mass media. Like drugs, communication media alter the way we interact with the world; they direct our attention in various ways, sometimes enabling certain behaviors and experiences, and prohibiting others. The contributors to this cutting-edge collection apply media ecological concepts to consider how drugs function as communication technologies; literally media in and for the human sensorium. In these essays, drugs are considered as communication media in a practical sense, not merely in the metaphorical way they tend to be discussed in the popular press. Media and drugs are thus conceived as communicative tools that enhance and/or inhibit physical, social and symbolic experience - our ways of seeing and being in the world. Drugs & Media: New Perspectives on Communication, Consumption and Consciousness is the first book to examine this parallel, promoting a critical awareness of the significant impact of drugs and media on individuals, society and our wider human culture. |
| canadian agency for drugs and technologies in health: EMBEC & NBC 2017 Hannu Eskola, Outi Väisänen, Jari Viik, Jari Hyttinen, 2017-06-12 This volume presents the proceedings of the joint conference of the European Medical and Biological Engineering Conference (EMBEC) and the Nordic-Baltic Conference on Biomedical Engineering and Medical Physics (NBC), held in Tampere, Finland, in June 2017. The proceedings present all traditional biomedical engineering areas, but also highlight new emerging fields, such as tissue engineering, bioinformatics, biosensing, neurotechnology, additive manufacturing technologies for medicine and biology, and bioimaging, to name a few. Moreover, it emphasizes the role of education, translational research, and commercialization. |
| canadian agency for drugs and technologies in health: Science, Technology and Innovation Indicators in a Changing World Responding to Policy Needs OECD, 2007-09-20 A conference proceedings that discusses policy needs, measurement issues, and some of the challenges in describing cross-cutting and emerging topics in science, technology and innovation. |
| canadian agency for drugs and technologies in health: ECSCW 2007 Liam J. Bannon, Ina Wagner, Carl Gutwin, Richard H.R. Harper, Kjeld Schmidt, 2007-09-20 The emergence and widespread use of personal computers and network technologies have seen the development of interest in the use of computers to support cooperative work. This volume presents the proceedings of the tenth European conference on Computer Supported Cooperative Work (CSCW). This is a multidisciplinary area that embraces the development of new technologies grounded in actual cooperative practices. These proceedings contain a collection of papers addressing novel interaction technologies for CSCW systems, new models and architectures for groupware systems, studies of communication and coordination among mobile actors, studies of cooperative work in complex settings, studies of groupware systems in actual use in real-world settings, and theories and techniques to support the development of cooperative applications. The papers present emerging technologies alongside new methods and approaches to the development of this important class of applications. |
| canadian agency for drugs and technologies in health: HEALTHCARE MARKETING RELOADED IN GLOBAL CONTEXT: SERVED WITH SYNERGY OF TECHNOLOGICAL AND SOCIO-ECONOMIC DEVELOPMENTS Bikram Prasad, Dr. Indrajit Ghosal, Dr. Abhishek Tripathi, Dr. Sheetal Desai, |
| canadian agency for drugs and technologies in health: Edelman and Kudzma's Canadian Health Promotion Throughout the Life Span - E-Book Shannon Dames, Marian Luctkar-Flude, Jane Tyerman, 2020-07-23 Learn the ins and outs of health promotion and disease prevention in Canada with Edelman and Kudzma's Canadian Health Promotion Throughout the Life Span. This all-new, comprehensive text grounds you in the Canadian health objectives for promotion and prevention which aims to improve the health of the entire population and to reduce health inequities among population groups. Among the text's chapters you'll find extensive coverage of growth and development throughout the life span — including coverage of the normal aspects, the unique problems, and the health promotion needs that are found in each age and stage of development. Separate chapters discuss each population group — the individual, the family, and the community — and highlight the unique aspects of caring for each of these groups. In all, this comprehensive and culturally relevant text provides all the tools needed to stay up on the latest research and topics in Canadian health promotion. |
| canadian agency for drugs and technologies in health: National Institute for Health and Clinical Excellence Great Britain: Parliament: House of Commons: Health Committee, 2008-01-10 Healthcare systems have been confronted by multiple, often conflicting, guidelines on the use of medical technologies. The National Institute for Clinical Excellence (NICE) was established in 1999 to address these problems in England. This work looks at what it does, how it works, changes made since its establishment, and the challenges it faces. |
| canadian agency for drugs and technologies in health: Pharmaceutical Public Policy Thomas R. Fulda, Alan Lyles, Albert I Wertheimer, 2016-04-14 As the most common health-care intervention, prescription drug use shares the most important characteristics of the health-care system in the United States. When everything works well, it makes possible breathtakingly successful applications of science to the prevention and cure of human suffering. But everything doesn‘t always work well. Pharmaceu |
| canadian agency for drugs and technologies in health: Newfoundland and Labrador Stephen Bornstein, John Abbott, Victor Maddalena, Aimee Letto, Melissa Sullivan, Pablo Navarro, 2021-10-01 There is not, and has never been, a single Canadian health system. Part of a series on the health systems of Canada’s provinces and territories, Newfoundland and Labrador: A Health System Profile provides a critical analysis of how the single-payer health care system has been implemented in the country’s youngest province. Examining the way the province’s health services are organized, funded, and delivered, the authors focus on the challenges involved in providing effective health care in a setting characterized by a large, decentralized territory; a small population, much of which is widely distributed in a large number of rural communities and small towns; and comparatively limited fiscal capacity and health human resources. Drawing on maps, figures, and collected data, this book documents the hesitant and limited ways in which Newfoundland and Labrador has sought to deal with the challenges and difficulties that the system has experienced in responding to recent changes in demography, economics, and medical technology. |
| canadian agency for drugs and technologies in health: Issues in Family Medicine Research and Practice: 2013 Edition , 2013-05-01 Issues in Family Medicine Research and Practice: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Internal Medicine. The editors have built Issues in Family Medicine Research and Practice: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Internal Medicine in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Family Medicine Research and Practice: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| canadian agency for drugs and technologies in health: Health Insurance Systems Thomas Rice, 2021-05-06 Health Insurance Systems: An International Comparison offers united and synthesized information currently available only in scattered locations - if at all - to students, researchers, and policymakers. The book provides helpful contexts, so people worldwide can understand various healthcare systems. By using it as a guide to the mechanics of different healthcare systems, readers can examine existing systems as frameworks for developing their own. Case examples of countries adopting insurance characteristics from other countries enhance the critical insights offered in the book. If more information about health insurance alternatives can lead to better decisions, this guide can provide an essential service. - Delivers fundamental insights into the different ways that countries organize their health insurance systems - Presents ten prominent health insurance systems in one book, facilitating comparisons and contrasts, to help draw policy lessons - Countries included are Australia, Canada, France, Germany, Japan, the Netherlands, Sweden, Switzerland, the United Kingdom, and the United States - Helps students, researchers, and policymakers searching for innovative designs by providing cases describing what countries have learned from each other |
| canadian agency for drugs and technologies in health: The Dictionary of Health Economics, Second Edition Anthony J. Culyer, 2010-01-01 ''Another masterpiece in health economics from a doyen in the field, this expanded and updated dictionary will undoubtedly become a standard reference work for scholars, practitioners and others working in this area. The definitions are concise, the coverage is comprehensive, the cross-referencing is excellent, and the subject and name indexes greatly assist navigation of this substantial tome. You will want to keep this one within arm''s reach.'' Jim Butler, Australia National University ''Health economics and health service research as well as health care policy, delivery and finance rely on a dizzying array of terms drawn from a diverse set of disciplines including (but not limited) to economics, epidemiology, risk science and statistics. Moreover, the health and health care systems are replete with acronyms and specialized institutions. The Dictionary of Health Economics provides the most comprehensive set of definitions and explanations of these terms available. It is a fantastic resource for anyone working in any health related field.'' Michael Chernew, Harvard Medical School, US ''This dictionary is unique. What other dictionary borders on being an enjoyable read? Its breadth is quite astonishing. It is also very clearly a health economics dictionary and will allow those in mainstream economics, in the other social sciences and in health sciences and health care to understand and be better able to communicate with health economists. It will also be a most useful addition to the bookshelves of health economists like myself.'' Gavin Mooney, University of Sydney, Australia ''This book is a welcome addition for graduate students or professionals interested in the taxonomy of health care.'' David Cutler, Harvard University, US ''Health economics is at the crossroads of medicine, economics, statistics, insurance, and the law. This often makes for difficult reading. But help is now available thanks to this amazingly comprehensive Dictionary of Health Economics. I for one ran into several entries that I did not or did not fully understand, but the very clear explanations changed that within a few moments! This Dictionary is a true service to the scientific community.'' Peter Zweifel, University of Zurich, Switzerland ''The Dictionary provides a comprehensive overview and authoritative yet accessible explanation of important terms and concepts from the increasingly important field of health economics. This excellent work will enable many entering this field, students and professionals alike, to quickly yet thoroughly grasp the meaning of the health economics jargon, facilitating study and (multi-disciplinary) co-operation. Anthony Culyer is sharing his impressive knowledge in this field in a clear and user-friendly fashion, hopefully to the benefit of many readers.'' Werner Brouwer, Erasmus University Rotterdam, the Netherlands ''An essential book to steer the student away from a minefield of inaccurate and woolly definitions and an important resource of the practitioner of health economics. A book that offers the reader accuracy and rigour in the definitions it provides of key terms in health economics alongside ready access.'' John Brazier, University of Sheffield, UK This second edition of Culyer''s authoritative Dictionary of Health Economics brings the material up to date and adds large amounts of new information. Some definitions have been revised. There are over 700 new entries. The Dictionary now also contains extensive references to the literature to identify original source material or to provide illustrations of the headword in use. The bibliography comprises some 1,000 items. In view of the huge growth in cost-effectiveness studies and the continuing variability in their quality, an appendix lists 100 high quality cost-effectiveness studies from all parts of the world. There are now many more entries and references relating to the developing world. New and separate subject and name indices provide supplementary means of searching the material and identifying individuals who have contributed significantly to the oeuvre. |
| canadian agency for drugs and technologies in health: Pharmacology for Pharmacy Technicians - E-Book Kathy Moscou, Karen Snipe, 2024-01-18 Build a solid foundation in pharmacology with this all-in-one resource! Combining a comprehensive textbook with workbook exercises, Pharmacology for Pharmacy Technicians, 4th Edition helps you understand the principles of pharmacology and apply them to the daily activities and challenges seen in the practice setting. Full-color photos and illustrations make it easier to master concepts, and an in-depth review designed specifically for pharmacy technicians meets the requirements of the American Society of Health-System Pharmacists (ASHP) for anatomy and physiology and pharmacology. Written by a pharmacist and a pharmacy technician, Kathy Moscou and Karen Snipe — each with extensive experience in the field — this book helps you master the expanding role of the pharmacy technician and launch a successful and rewarding career in Pharmacy Technology. - Comprehensive coverage aligns with advanced-level ASHP competencies for accreditation and prepares you for certification. - Practical Pharm Tech features include Tech Alerts highlighting drug look-alike and sound-alike issues, Tech Notes with need-to-know information on safe drug dispensing, and Technician's Corner critical thinking exercises. - Coverage of A&P and medical terminology is included within each body system unit. - Quick-reference, mini drug monographs are included within each body system and drug classification chapter, and include pill photos along with generic and trade names, strength of medication, route of administration, dosage form, dosing schedule, and warning labels. - Learning features in each chapter include learning objectives, key terms, key points, and review questions. - Exam preparation includes two 120-question online practice exams in addition to board-style review questions. - Summary drug tables provide generic/brand name, drug strengths and dosage forms, usual dose and dosing schedule, and warning labels for at-a-glance access to important information. - NEW! Updated drug information ensures you are familiar with the latest drug approvals and the latest dosage and prescription guidelines. - NEW! Coverage of changes in pharmacology includes the newest pharmaceutical laws, handling and dispensing of controlled substances, COVID-19 developments, and advances in vaccines. - NEW! Integrated workbook exercises by chapter provide vocabulary practice, review questions, and case studies in the text as well as critical thinking and research activities online. |
| canadian agency for drugs and technologies in health: Health Technology Assessment of Medical Devices World Health Organization, 2012-10-25 WHO and partners have been working towards devising an agenda, an action plan, tools and guidelines to increase access to appropriate medical devices. This document is part of a series of reference documents being developed for use at the country level. The series will include the following subject areas: * policy framework for health technology * medical device regulations * health technology assessment * health technology management * needs assessment of medical devices * medical device procurement * medical equipment donations * medical equipment inventory management * medical equipment maintenance * computerized maintenance management systems * medical device data * medical device nomenclature * medical devices by health-care setting * medical devices by clinical procedures * medical device innovation, research and development. These documents are intended for use by biomedical engineers, health managers, donors, nongovernmental organizations and academic institutions involved in health technology at the district, national, regional or global levels. HTA is the systematic evaluation of properties, effects, and/or impacts of health technology. Its main purpose is to inform technology-related policy-making in health care, and thus improve the uptake of cost-effective new technologies and prevent the uptake of technologies that are of doubtful value for the health system. It is one of three complementary functions to ensure the appropriate introduction and use of health technology. The other two components are regulation, which is concerned with safety and efficacy, and assessment of all significant intended as well as unintended consequences of technology use; and management, which is concerned with the procurement and maintenance of the technology during its life-cycle. The performance of health systems is strengthened when the linkages and exchange among these elements are clearly differentiated but mutually supportive. This document integrates health technology assessment into the WHO framework for evidence-informed policy-making. Health systems are strengthened when HTA is integrated into the human and material resources, data, transparent decision- and policy-making, and linked to the overall vision of equity and accountability. Good governance can rely on health technology assessment to provide a policy approach that is accountable for its decisions to the population. |
| canadian agency for drugs and technologies in health: Sultz and Young's Health Care USA: Understanding Its Organization and Delivery James A. Johnson, Kimberly S. Davey, Richard G. Greenhill, 2022-03-09 Overview of the United States Health Care System -- Historical and Benchmark Developments in American Health Care -- Public Policy and the Role of Government -- Financing Health Care -- The Healthcare Workforce -- Hospitals and Integrated Delivery Systems -- Ambulatory Care -- Long-term Care and Specialized Services -- Behavioral Health Services -- Public and Population Health -- Health Information Technology and Quality -- Health Services and Systems Research -- Preparedness and Emergency Management -- Rural Healthcare -- Health Care and The Future. |
| canadian agency for drugs and technologies in health: Decision Making in a World of Comparative Effectiveness Research Howard G. Birnbaum, Paul E. Greenberg, 2017-05-05 In the past decade there has been a worldwide evolution in evidence-based medicine that focuses on real-world Comparative Effectiveness Research (CER) to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on research findings, data and methods, Howard Birnbaum and Paul Greenberg (both of Analysis Group) have edited a book that provides a practical guide to decision making using the results of analysis and interpretation of CER. Decision Making in a World of Comparative Effectiveness contains chapters by senior industry executives, key opinion leaders, accomplished researchers, and leading attorneys involved in resolving disputes in the life sciences industry. The book is aimed at 'users' and 'decision makers' involved in the life sciences industry rather than those doing the actual research. This book appeals to those who commission CER within the life sciences industry (pharmaceutical, biologic, and device manufacturers), government (both public and private payers), as well as decision makers of all levels, both in the US and globally. |
Canada - Wikipedia
Other popular professional competitions include the Canadian Football League, National Lacrosse League, the Canadian Premier League, and the curling tournaments hosted by Curling …
Canada | History, Population, Immigration, Capital, & Currency
1 day ago · This fact, coupled with the grandeur of the landscape, has been central to the sense of Canadian national identity, as expressed by the Dublin-born writer Anna Brownell Jameson, …
Home - Canada.ca
Buying, selling and supporting Canadian. Find information on Made in Canada labels, how to buy Canadian and the benefits of shopping and travelling in Canada. Choose Canada. Canada, it’s …
Canada Maps & Facts - World Atlas
Jan 8, 2024 · Canadian Arctic: The Canadian Arctic encompasses Canada's northernmost parts, including parts of Nunavut, Northwest Territories, and Yukon. It is a vast, sparsely populated …
Canada - The World Factbook
6 days ago · Visit the Definitions and Notes page to view a description of each topic.
25 Things Canada is Known and Famous For - Hey Explorer
May 13, 2025 · The Canadian Rockies are full of sparkling glaciers, turquoise lakes, and winding roads. The region is home to some famous National Parks including Banff, Jasper, and Yoho. …
Canada - Simple English Wikipedia, the free encyclopedia
Around 38 million people live in Canada. About 90% of the Canadian population live within 100 miles (160 km) of the border with the United States. [28] This is because of climate and trade …
Canada | The Canadian Encyclopedia
The name “Canada,” is derived from the Iroquoian word kanata, meaning a village or settlement. On 13 August 1535, as Jacques Cartier was nearing Île d'Ant...
The Canada Guide | In-depth reference website for all things Canadian
The Canada Guide is an in-depth reference website for all things Canadian for student research, tourists, immigrants studying for citizenship and others.
Canadians - Wikipedia
Canadian culture has historically been influenced by European culture and traditions, especially British and French, and by its own indigenous cultures.
